根据公告内容，公司拟使用自有资金及金融机构回购专项借款，以集中竞价交易方式回购社会公众股 份，预计回购金额区间为 6000 万元至 1.2 亿元，回购价格上限为 23.98 元 / 股，回购期限为董事会审议 通过之日起 12 个月。此次回购股份将用于员工持股计划或股权激励、转换公司可转债，旨在进一步完 善公司治理结构，绑定核心团队利益，同时优化资本结构，增强发展韧性。 公告显示，2026 年 2 月 2 日，步长制药顺利完成首次回购。本次共回购股份 217.6 万股，占公司总股本 的 0.21%，回购价格区间为 16.75 元 / 股至 17.12 元 / 股，累计支付资金 3675.79 万元(不含交易费用)。 值得关注的是，本次实际回购价格显著低于 23.98 元 / 股的价格上限，体现出公司在回购操作中的高效 性与审慎性，实现了资金使用效率的最大化。 在资金保障方面，步长制药已与中国农业银行股份有限公司菏泽牡丹支行签署专项借款合同，获得 1 亿 元 3 年期回购专项贷款，结合公司充裕的自有资金，为后续回购计划的推进提供了充足的资金支持。 回购释放多重积极信号 兼顾短期市值维稳与长期战略发展 近期，步长制 ...

Core Viewpoint - Shandong Buchang Pharmaceutical's subsidiary, Luzhou Buchang, has signed an exclusive supply agreement with Malaysian company MEDISPEC, marking a significant step in the company's "Traditional Chinese Medicine Internationalization" strategy [1] Group 1: Internationalization Strategy - The signing of the agreement reflects the deepening of Buchang Pharmaceutical's internationalization strategy, with recent product registrations in Malaysia, Mongolia, and Indonesia [2] - The company's sales network now covers dozens of countries, including the US, Canada, and Vietnam, and is actively expanding into Latin America [2] - Buchang Pharmaceutical aims to make "Chinese prescriptions" an international medical option and promote traditional Chinese culture [2] Group 2: R&D and Product Development - Buchang Pharmaceutical is advancing in innovative drug development, with significant progress in its pipeline across biological, traditional Chinese, and chemical drugs [4] - The company has received approvals for 17 generic drugs in 2023, with over 170 products included in the 2025 National Medical Insurance Directory, including 73 exclusive products [4] - Exclusive products have generated over 10.3 billion yuan in sales in the first three quarters of 2025, providing strong support for ongoing innovation [4] Group 3: Shareholder Returns - The company has returned 7.948 billion yuan to shareholders through regular high dividends and share buybacks, exceeding the total IPO fundraising amount [5] - In 2025 alone, the company repurchased 6.6206 million shares, spending nearly 100 million yuan, and completed the cancellation of 51.47 million shares [5] Group 4: Social Responsibility - Buchang Pharmaceutical has sponsored the "Together, Build China's Heart" public welfare project for 18 consecutive years, providing medical assistance to over a million people [6] - The company emphasizes the dual focus on innovation and social responsibility, aiming to create greater social value while advancing pharmaceutical innovation [6]

Core Viewpoint - Recently, Buchang Pharma has gained market attention for its innovation in drug development, capital market returns, and commitment to public welfare, showcasing the company's responsibility and dedication in the pharmaceutical industry [1] Innovation Drug Pipeline - Buchang Pharma has made significant advancements in its innovation drug pipeline, covering three major areas: biopharmaceuticals, traditional Chinese medicine, and chemical drugs [2] - The company is accelerating the application of its first Class 1 new drug, Epoetin Alfa, targeting renal anemia and chemotherapy-induced anemia, which could fill a gap in the domestic long-acting EPO market valued at 15 billion [2] - The first biosimilar drug, Adalimumab injection, is under review, targeting multiple autoimmune diseases with substantial market potential [2] - The company is advancing its Class 1 biopharmaceutical BC001 for late-stage gastric cancer and has several targeted cancer drugs in critical clinical development stages [2][4] Traditional Chinese Medicine and Chemical Drug Expansion - In traditional Chinese medicine, the company has completed Phase II clinical trials for its Qi-tonifying granules and is set to start Phase II/III trials for its heart failure treatment granules in May 2025 [4] - In the chemical drug sector, Buchang Pharma has launched 17 new generic drugs in 2023, including products that target a 20 billion market for antiviral drugs and expand its muscle relaxant market [4] - The company has successfully renewed contracts for exclusive products in the 2025 National Medical Insurance Directory, with total sales exceeding 10.3 billion in the first three quarters [4] Shareholder Returns - Buchang Pharma has established a stable return mechanism for investors, with cumulative dividends reaching 7.948 billion and share buybacks totaling 1.744 billion since its listing [5] - In 2025, the company has repurchased 6.6206 million shares, with a total repurchase amount nearing 100 million, demonstrating confidence in its future development [5] Corporate Social Responsibility - Since its inception, Buchang Pharma has adhered to its mission of "creating health for humanity," actively engaging in social responsibility through the "Together, Build China's Heart" initiative for 18 years [6] - The initiative has expanded from congenital heart disease to various medical fields, providing comprehensive medical assistance to over 1 million patients [6] - The company has contributed nearly 33 billion in taxes nationwide, supporting regional economic development [6] Future Outlook - The chairman of Buchang Pharma, Zhao Tao, emphasized the company's commitment to innovation-driven development and social responsibility, aiming to lead industry growth and create greater social value [7]

Core Viewpoint - The company is facing a lawsuit related to a contract dispute involving approximately 652 million yuan, which may impact its inventory valuation and future profits [1] Group 1: Legal Issues - The company's subsidiary, Shanghai HePu, has filed a lawsuit against Jiemai Shanghai due to a contract dispute over the distribution agreement, with the court accepting the case [1] - The lawsuit involves around 550 million yuan worth of inventory that has not been transferred, posing a risk of inventory impairment [1] Group 2: Financial Performance - The company has experienced a decline in revenue for four consecutive years, with revenues of 160.07 billion yuan in 2020 dropping to an estimated 110.06 billion yuan in 2024 [2] - In the first three quarters of 2025, the company reported total revenue of 8.469 billion yuan, a slight decrease of 0.54% year-on-year, while net profit increased significantly by 177.54% to 868 million yuan [4] Group 3: Strategic Developments - The company plans to acquire six health food products for 7.5 million yuan to expand its presence in the health industry [5] - The acquisition involves obtaining the technical ownership of the products from six different independent entities, ensuring commercial production [6] Group 4: Market Performance - As of December 29, the company's stock price decreased by 1.16% to 16.26 yuan per share, with a total market capitalization of approximately 17.147 billion yuan [6]

Core Viewpoint - The recognition of "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" awarded to the company reflects its dual leadership in industry innovation and social responsibility, serving as a model for sustainable development in the pharmaceutical sector [1][4][13]. Group 1: Innovation and R&D - The company has been awarded "Annual Drug R&D Innovation Enterprise" due to its over 30 years of dedication to the pharmaceutical industry, with innovation as its core development engine [6]. - In 2018, the company announced a strategic transformation from a marketing-driven model to a product and technology-driven approach, expanding from traditional Chinese medicine to biopharmaceuticals, chemical drugs, medical devices, and internet medicine [6]. - The R&D investment reached 717 million yuan in 2024, an increase of 8.58% year-on-year, emphasizing the importance of continuous investment in innovation [6]. - As of mid-2025, the company holds 457 valid patents and has over 200 products under development, establishing a solid foundation for industry innovation [7]. - The company’s flagship products, including "Nerve and Heart Capsule," "Stable Heart Granule," and "Dan Hong Injection," generated a total sales revenue of 5.83 billion yuan in 2024, with a market share ranking in the top five for cardiovascular traditional Chinese medicine [7][8]. Group 2: Social Responsibility and Public Welfare - The company has been recognized as "Annual Excellent Public Welfare Enterprise" for its commitment to social responsibility, integrating public welfare into its core business [10][11]. - The "Together to Build a Chinese Heart" public welfare project has been ongoing for 18 years, benefiting over 1 million people in Tibetan regions through medical support and health initiatives [11][12]. - The company’s public welfare efforts are not merely financial donations but involve deep collaboration with its business strategy, enhancing both social impact and corporate value [12]. - Since its establishment, the company has contributed nearly 33 billion yuan in taxes, supporting local economic development [12]. Group 3: Future Outlook - The dual recognition of "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" exemplifies the company's successful "innovation + public welfare" dual-driven development model [13]. - The company aims to deepen its global layout and continue breakthroughs in biopharmaceuticals and vaccines, while expanding its public welfare projects, contributing to the "Healthy China" strategy and high-quality development of the pharmaceutical industry [13].

Core Insights - The company, Buchang Pharma, has been awarded "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" at the 2025 9th Century Health Industry Competitiveness Research "Sunshine" Case, highlighting its dual leadership in drug innovation and social responsibility [1][6] Group 1: Innovation and R&D - Buchang Pharma's recognition as "Annual Drug R&D Innovation Enterprise" is a result of over 30 years of commitment to the pharmaceutical industry, with innovation as its core development engine [2] - The company announced a strategic transformation in 2018, shifting from a marketing-driven model to a product and technology-driven approach, expanding from traditional Chinese medicine to biopharmaceuticals, chemical drugs, and medical devices [2] - In 2024, the company's R&D investment reached 717 million yuan, an increase of 8.58% year-on-year, with a focus on both independent innovation and collaborative research [2] - As of mid-2025, Buchang Pharma holds 457 valid patents and has over 200 products in development, laying a solid foundation for industry-wide innovation [2] Group 2: Product Portfolio - The company has established a product portfolio that covers major disease areas, including cardiovascular, gynecological, urological, diabetes, and oncology [3] - Key proprietary products, including Naoxin Tong Capsule, Stabilizing Heart Granules, and Danhong Injection, generated sales of 5.83 billion yuan in 2024 and 3.12 billion yuan in the first half of 2025, ranking in the top five in the cardiovascular traditional Chinese medicine market [3] - These key products are included in the 2024 National Medical Insurance Directory, ensuring reimbursement support and facilitating market share expansion [3] Group 3: Social Responsibility and Public Welfare - The company has been actively engaged in public welfare for over 20 years, focusing on social responsibility as a core component of its business strategy [6] - The "Together to Build a Chinese Heart" project has provided assistance to over 100 million people in Tibetan and other underdeveloped regions, showcasing the company's commitment to healthcare and community support [6][7] - Buchang Pharma's public welfare initiatives are integrated with its business strategy, enhancing brand recognition and expanding market reach while addressing healthcare needs in underserved areas [8] - Since its establishment, the company has contributed nearly 33 billion yuan in taxes, supporting local economic development [8]

Group 1 - The company successfully renewed the inclusion of its products, Xuanfei Baidu Granules and Danhong Injection, in the National Medical Insurance Catalog for 2025 [1][3] - Xuanfei Baidu Granules are indicated for clearing heat and detoxifying, used for epidemic diseases caused by damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1][2] - Danhong Injection is indicated for activating blood circulation and relieving obstruction, used for chest pain and stroke caused by blood stasis, with symptoms including chest pain, palpitations, and limb numbness [2] Group 2 - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with specific execution requirements to be determined by government departments [3] - The sales performance of the drugs may be influenced by multiple factors, including changes in the market environment, leading to uncertainty [3]

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. successfully renewed the inclusion of its products Xuanfei Baidu Granules and Danhong Injection in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market position and sales performance [1][3]. Product Information - Xuanfei Baidu Granules are indicated for clearing lung heat and detoxifying, used for damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1]. - Danhong Injection is used for promoting blood circulation and alleviating pain, indicated for conditions such as chest pain and stroke, with symptoms including chest tightness and limb numbness [2]. Sales Impact - The National Medical Insurance Directory will be officially implemented on January 1, 2026, and the sales performance of the drugs may be influenced by various market factors, indicating a level of uncertainty [3].

Core Viewpoint - The company, Buchang Pharma, successfully retained its drugs Xuanfei Baidu Granules and Danhong Injection in the National Medical Insurance Directory for 2025, ensuring continued access to these products under national health insurance programs [1] Group 1: Drug Information - Xuanfei Baidu Granules are indicated for clearing heat and detoxifying the lungs, used for epidemic diseases caused by damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1] - Danhong Injection is used for promoting blood circulation and alleviating blood stasis, indicated for conditions such as chest pain and stroke, with symptoms including chest tightness and limb numbness [1]

Group 1 - The article highlights the achievements of Zhao Buchang in the field of traditional Chinese medicine, particularly his contributions to the development of innovative products like brain-heart capsules and stable heart granules [2][4] - It emphasizes the ambition for high-quality development in traditional Chinese medicine, focusing on scientific, clinical, preventive, and economic values to support a healthy China [4][5] - The narrative reflects a commitment to delivering quality medicine to the public and leveraging high technology to enhance the traditional medicine industry, showcasing a vision for the future of Chinese medicine [5] Group 2 - The article mentions the "Step Chang Pharmaceutical 75 Blueprint," indicating a strategic plan for the company's future growth and expansion in the global market [4] - It underscores the importance of addressing cardiovascular diseases through the "brain-heart co-treatment" approach, marking a new era in healthcare [5]